.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has submitted to debut on everyone market.The Eli Lilly-partnered biotech expect to note on the Nasdaq under the symbolic representation "BIOA," according to documentations filed along with the Stocks and Substitution Compensation. The company has actually not publicly discussed an expected monetary quantity for the offering.The clinical-stage company boasts lead prospect azelaprag, an orally delivered small molecule slated to get into stage 2 testing in combination with semaglutide-- sold by Novo Nordisk under trademark name Wegovy for fat burning-- in the first fifty percent of following year. Semaglutide is also marketed as Ozempic and also Rybelsus by Novo for diabetic issues.
Apelin receptor agonist azelaprag is actually designed to incorporate properly along with GLP-1 medications, improving weight reduction while protecting muscle mass. The investigational medication was found to become well-tolerated one of 265 individuals all over 8 stage 1 trials, depending on to BioAge.Earlier, BioAge amassed the assistance of Lilly to operate a test blending azelaprag with the Major Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is actually marketed for diabetes mellitus as Mounjaro and Zepbound for weight reduction. The companions are actually currently administering a stage 2 trial of azelaprag and also tirzepatide, with topline outcomes assumed in the third quarter of 2025.The biotech is actually additionally preparing a the hormone insulin sensitivity proof-of-concept test assessing azelaprag as a monotherapy in the initial one-half of following year to sustain possible evidence development. Moreover, the company plans to ask the FDA for approval in the 2nd one-half of 2025 to introduce human testing for an NLRP3 prevention targeting metabolic ailments and also neuroinflammation.BioAge's foreseed move to everyone market complies with a small uptick in planned biotech IPOs coming from Bicara Rehabs as well as Zenas Biopharma. Zooming out, the current IPO landscape is actually a "combined photo," with top quality companies still debuting on everyone markets, simply in minimized numbers, depending on to PitchBook.